scholarly journals Development and optimization of an injectable formulation of copper diethyldithiocarbamate, an active anticancer agent

2017 ◽  
Vol Volume 12 ◽  
pp. 4129-4146 ◽  
Author(s):  
Mohamed Wehbe ◽  
Malathi Anantha ◽  
Minghan Shi ◽  
Ada Wai-yin Leung ◽  
Wieslawa Dragowska ◽  
...  
Keyword(s):  
Anticancer Agent ◽  
Injectable Formulation ◽  
Copper Diethyldithiocarbamate

The Therapeutic and Diagnostic Value of Fluorine

2020 ◽  
Vol 4 (1) ◽  
pp. 17-29
Author(s):  
Isma Attique ◽  
Shabbir Hussain ◽  
Muhammad Amjad ◽  
Khalida Nazir ◽  
Muhammad Shahid Nazir
Keyword(s):  
Anticancer Agent ◽  
Chemotherapeutic Agent ◽  
Functional Materials ◽  
Diagnostic Value ◽  
Vital Role ◽  
Malignant Growth ◽  
Medical Field ◽  
Active Nucleus ◽  
Broad Application ◽  
Tracer Atom

Fluorine has a useful positron transmitting isotope and it enjoys broad application in the medical field. It is utilized in fluorinated agents,therapeutic sciences and steroid field. Fluorine incorporation viafluoroalkylation is a useful approach in the development of new functional materials and in drug design. Fluorine also plays its role as an anticancer agent and is a successful chemotherapeutic agent for certain sorts of malignant growth. 5-fluorouracil plays a vital role in the treatment of cancer. 18 Facts as a radio label tracer atom in PET imaging. 19 F has the second most sensitive and stable NMR-active nucleus.

Vitamin D as potential therapeutic anticancer agent

2018 ◽  
pp. 1-3
Keyword(s):  
Vitamin D ◽  
Anticancer Activity ◽  
Anticancer Agent ◽  
Antitumor Agents ◽  
Metastatic Potential ◽  
Anticancer Properties ◽  
Chemotherapy Agents

The role of vitamin D is implicated in carcinogenesis through numerous biological processes like induction of apoptosis, modulation of immune system inhibition of inflammation and cell proliferation and promotion of cell differentiation. Its use as additional adjuvant drug with cancer treatment may be novel combination for improved outcome of different cancers. Numerous preclinical, epidemiological and clinical studies support the role of vitamin D as an anticancer agent. Anticancer properties of vitamin D have been studied widely (both in vivo and in vitro) among various cancers and found to have promising results. There are considerable data that indicate synergistic potential of calcitriol and antitumor agents. Possible mechanisms for modulatory anticancer activity of vitamin D include its antiproliferative, prodifferentiating, and anti-angiogenic and apoptic properties. Calcitriol reduces invasiveness and metastatic potential of many cancer cells by inhibiting angiogenesis and regulating expression of the key molecules involved in invasion and metastasis. Anticancer activity of vitamin D is synergistic or additive with the antineoplastic actions of several drugs including cytotoxic chemotherapy agents like paclitaxel, docetaxel, platinum base compounds and mitoxantrone. Benefits of addition of vitamin D should be weighed against the risk of its toxicity.

Cellular Pharmacology of DUP-785, a New Anticancer Agent

1989 ◽  
Vol 1 (6) ◽  
pp. 381-387 ◽  
Author(s):  
Lawrence W. Anderson ◽  
John M. Strong ◽  
Richard L. Cysyk
Keyword(s):  
Anticancer Agent ◽  
Cellular Pharmacology

Current Scenario in Structure and Ligand-Based Drug Design on Anti-colon Cancer Drugs

2019 ◽  
Vol 24 (32) ◽  
pp. 3829-3841 ◽  
Author(s):  
Lakshmanan Loganathan ◽  
Karthikeyan Muthusamy
Keyword(s):  
Drug Discovery ◽  
Drug Design ◽  
Anticancer Agent ◽  
Computational Power ◽  
Cancer Drugs ◽  
Recent Advances ◽  
Anti Cancer ◽  
Drug Designing ◽  
Current Scenario ◽  
Molecular Modeling Studies

Worldwide, colorectal cancer takes up the third position in commonly detected cancer and fourth in cancer mortality. Recent progress in molecular modeling studies has led to significant success in drug discovery using structure and ligand-based methods. This study highlights aspects of the anticancer drug design. The structure and ligand-based drug design are discussed to investigate the molecular and quantum mechanics in anti-cancer drugs. Recent advances in anticancer agent identification driven by structural and molecular insights are presented. As a result, the recent advances in the field and the current scenario in drug designing of cancer drugs are discussed. This review provides information on how cancer drugs were formulated and identified using computational power by the drug discovery society.

Current Studies of Aspirin as an Anticancer Agent and Strategies to Strengthen its Therapeutic Application in Cancer

2020 ◽  
Vol 26 ◽  
Author(s):  
Phuong H.L. Tran ◽  
Beom-Jin Lee ◽  
Thao T.D. Tran
Keyword(s):  
Anticancer Agent ◽  
Mechanisms Of Action ◽  
Aspirin Therapy ◽  
Therapeutic Application ◽  
Cancer Treatments ◽  
Anticancer Properties ◽  
Cancer Management ◽  
Risk Of Bleeding ◽  
The Past ◽  
Inflammatory Drugs

: Aspirin has emerged as a promising intervention in cancer in the past decade. However, there are existing controversies regarding the anticancer properties of aspirin as its mechanism of action has not been clearly defined. In addition, the risk of bleeding in the gastrointestinal tract from aspirin is another consideration that requires medical and pharmaceutical scientists to work together to develop more potent and safe aspirin therapy in cancer. This review presents the most recent studies of aspirin with regard to its role in cancer prevention and treatment demonstrated by highlighted clinical trials, mechanisms of action as well as approaches to develop aspirin therapy best beneficial to cancer patients. Hence, this review provides readers with an overview of aspirin research in cancer that covers not only the unique features of aspirin, which differentiates aspirin from other non-steroidal anti-inflammatory drugs (NSAIDs), but also strategies that can be used in the development of drug delivery systems carrying aspirin for cancer management. These studies convey optimistic messages on continuing efforts of scientist on the way of developing an effective therapy for even patients with a low response to current cancer treatments.

Extending Natures Leads: The Anticancer Agent Ellipticine

2004 ◽  
Vol 4 (2) ◽  
pp. 149-172 ◽  
Author(s):  
Nichola Garbett ◽  
David Graves
Keyword(s):  
Anticancer Agent
Sign in / Sign up

Export Citation Format

Share Document